Q3 EPS Estimates for Journey Medical Lifted by Roth Capital

Journey Medical Co. (NASDAQ:DERM) – Equities research analysts at Roth Capital boosted their Q3 2025 EPS estimates for shares of Journey Medical in a research note issued to investors on Thursday, March 27th. Roth Capital analyst J. Wittes now forecasts that the company will earn $0.10 per share for the quarter, up from their prior estimate of $0.09. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2025 earnings at $0.16 EPS and FY2029 earnings at $5.83 EPS.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings data on Wednesday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.30. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The firm had revenue of $14.30 million for the quarter, compared to analysts’ expectations of $14.21 million.

Separately, Alliance Global Partners reaffirmed a “buy” rating on shares of Journey Medical in a research report on Thursday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $9.67.

Journey Medical Stock Up 3.2 %

DERM stock opened at $6.11 on Friday. The firm has a fifty day moving average price of $5.09 and a two-hundred day moving average price of $5.16. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. Journey Medical has a 1-year low of $3.20 and a 1-year high of $6.89. The firm has a market cap of $127.64 million, a price-to-earnings ratio of -6.50 and a beta of 0.97.

Insiders Place Their Bets

In other Journey Medical news, CEO Claude Maraoui sold 23,508 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $5.19, for a total value of $122,006.52. Following the completion of the transaction, the chief executive officer now owns 2,139,922 shares in the company, valued at approximately $11,106,195.18. This represents a 1.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 105,831 shares of company stock valued at $536,622 over the last three months. Company insiders own 13.16% of the company’s stock.

Hedge Funds Weigh In On Journey Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kovitz Investment Group Partners LLC bought a new stake in Journey Medical during the 3rd quarter valued at $66,000. Cetera Investment Advisers increased its holdings in shares of Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after purchasing an additional 2,478 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Journey Medical during the fourth quarter valued at about $80,000. Citadel Advisors LLC acquired a new stake in Journey Medical in the fourth quarter worth about $174,000. Finally, Geode Capital Management LLC grew its position in Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after buying an additional 12,882 shares in the last quarter. 7.25% of the stock is currently owned by institutional investors and hedge funds.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.